Aesica
Aesica will be joining Britest in a collaboration where members share knowledge and risk in defining innovative solutions to key manufacturing challenges. In particular, Aesica will be utilising Britest’s expertise to identify new approaches and technologies that drive major improvements in API manufacturing processes.
Britest has already engaged with 22 leading global chemical and pharmaceutical organisations together with a number of academic organisations. The partnerships are designed to utilise and further develop Britest’s tools and methodologies to support whole process understanding.
The Aesica Innovation Board (AIB) aims to identify and commercialise new technologies that help to bridge the growing R&D gap though industry and academic collaborations. Joining Britest will increase the AIB’s access to applicable, relevant technologies and strengthen the organisation’s relationships throughout the industry.
Dr. Barrie Rhodes, Aesica Director of Technology Development, said: “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key API process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”
Sue Fleet, Britest CEO, said: “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”
Aesica Pharmaceuticals Ltd, +44 191 218 1960, info@aesica-pharma.com, www.aesica-pharma.com.